Osama A Alzuman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Osama A Alzuman has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Abdulaziz Ageel Alageel
Microbiology Department, Pathology & Clinical Laboratory Medicine Administration, King Fahad Medical City, Riyadh, Saudi Arabia
1 shared publicationAbeer Odah AlMazyad
Microbiology Department, Pathology & Clinical Laboratory Medicine Administration, King Fahad Medical City, Riyadh, Saudi Arabia
1 shared publication- Ahlam Alghamdi
Department of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Abdulrahman University, P.O. Box 84428, Riyadh 11671, Saudi Arabia
1 shared publication Ahmed A Alrashed
Department of Clinical Pharmacy, King Fahad Medical City, Riyadh, Saudi Arabia
1 shared publicationAhmed Rashed Alsaegh
Department of Clinical Pharmacy, King Saud Medical City, Riyadh, Saudi Arabia
1 shared publication- Alnada Ibrahim
Department of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia
1 shared publication
Latest Publications
- Open Access
- 1 August 2026
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 19, 1-13
Clinical Characteristics, Antifungal Therapy, and Outcomes of Candida auris Candidemia: A Two-Center Cohort Study
Background: Candida auris has become a growing concern in hospital settings because of its resistance to multiple antifungal drugs. This study investigated the clinical features, treatment patterns, and outcomes of patients diagnosed with C. auris candidemia at two medical centers in Riyadh, Saudi Arabia. Methods: A two centres, retrospective cohort study which includes adult patients who had positive blood cultures for C. auris. The analysis covered patient characteristics, antifungal treatments, and outcomes. Results: The cohort consisted of 228 cases with C. auris candidemia 51.4% of whom were male. The average age of patients was 61.9± 17.8 years, and common comorbidities included hypertension (59.2%) and diabetes (50.0%). ICU care was needed for 68.8% of the patients. Fluconazole resistance was high (77%), while echinocandins showed > 90% susceptibility. Patients who received monotherapy had faster clearance (median = 4; IQR = 3– 5) compared to combination therapy (median = 5; IQR = 3.75– 8) (p= 0.013). Fewer recurrences were observed in monotherapy (11.1%) compared to those on combination therapy (23.7%) (p= 0.021). Survival was significantly lower among patients with high SOFA scores (p=0.027). Conclusion: C. auris candidemia remains a major clinical challenge due to its drug resistance and the severity of illness in affected patients. Echinocandins continue to be the preferred first-line treatments, and using SOFA scores may help in predicting patient outcomes and guiding treatment plans.
- 1 August 2026
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 19, 1-13
Open AccessClinical Characteristics, Antifungal Therapy, and Outcomes of Candida auris Candidemia: A Two-Center Cohort Study
Background: Candida auris has become a growing concern in hospital settings because of its resistance to multiple antifungal drugs. This study investigated the clinical features, treatment patterns, and outcomes of patients diagnosed with C. auris candidemia at two medical centers in Riyadh, Saudi Arabia. Methods: A two centres, retrospective cohort study which includes adult patients who had positive blood cultures for C. auris. The analysis covered patient characteristics, antifungal treatments, and outcomes. Results: The cohort consisted of 228 cases with C. auris candidemia 51.4% of whom were male. The average age of patients was 61.9± 17.8 years, and common comorbidities included hypertension (59.2%) and diabetes (50.0%). ICU care was needed for 68.8% of the patients. Fluconazole resistance was high (77%), while echinocandins showed > 90% susceptibility. Patients who received monotherapy had faster clearance (median = 4; IQR = 3– 5) compared to combination therapy (median = 5; IQR = 3.75– 8) (p= 0.013). Fewer recurrences were observed in monotherapy (11.1%) compared to those on combination therapy (23.7%) (p= 0.021). Survival was significantly lower among patients with high SOFA scores (p=0.027). Conclusion: C. auris candidemia remains a major clinical challenge due to its drug resistance and the severity of illness in affected patients. Echinocandins continue to be the preferred first-line treatments, and using SOFA scores may help in predicting patient outcomes and guiding treatment plans.